MindMed

MNMDNASDAQExtreme Risk

Developing pharmaceutically optimized psychedelic-derived therapies. Lead compound MM120 is a purified, precisely dosed form of lysergide (LSD) in an orally disintegrating tablet, targeting anxiety and depression without the recreational baggage — administered in a clinical setting under medical supervision.

Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Market cap

Small cap

Cash position

$260M as of Q4 2025

~22 months runway (derived)

Revenue status

pre revenue

Pipeline assets

2 programs

Trade MNMD commission-free on Webullvia Webull · Affiliate

What does MindMed do?

MindMed is developing what could be the most radical new approach to treating anxiety in decades: a single supervised dose of a psychedelic medicine that relieves anxiety for months. Their lead drug, MM120, is a pharmaceutically pure, precisely dosed form of lysergide (yes, related to LSD) given as a dissolving tablet under medical supervision. This isn't recreational — it's a carefully controlled clinical experience lasting about 8-12 hours in a medical facility. The remarkable thing: in Phase 2 trials, patients who received just ONE dose experienced significant anxiety reduction that lasted at least 12 weeks. Current anxiety medications (like Lexapro or Zoloft) require daily pills for life and take 4-6 weeks to start working. The FDA was impressed enough to grant MM120 Breakthrough Therapy designation for generalized anxiety disorder (GAD), which means they believe it may offer a substantial improvement over existing treatments and will expedite the review process. Now here's the investor reality: 2026 is pure binary. MindMed is running two Phase 3 trials — Voyage and Panorama — that will definitively answer whether this works in large, rigorous studies. If both succeed, MindMed goes from speculative penny stock to legitimate drug company with a path to a $4 billion market. If either fails, the stock likely drops 50%+ and the company may not survive. This is the definition of high-risk, high-reward biotech investing. The science is genuinely exciting, but psychiatry trials are notoriously difficult because the placebo effect is so strong. Many promising psychiatric drugs have failed in Phase 3 despite great Phase 2 results.

What to watch

1

Voyage Phase 3 topline data — the single most important event. Look for statistically significant HAM-A score reduction vs. placebo at 12 weeks

2

Placebo response rate — if placebo patients improve >35% on HAM-A, even a good drug can fail to show statistical significance

3

Duration of effect — does the single-dose benefit persist to the 12-week primary endpoint, or does it fade?

4

Safety and tolerability — any serious adverse events during the supervised session could doom the program

5

Regulatory feedback on REMS requirements — overly restrictive distribution rules could limit commercial viability even with approval


Pipeline

DrugIndicationPhaseExpected data
MM120 (lysergide D-tartrate ODT)Generalized anxiety disorder (GAD)Phase 3Voyage: H1 2026, Panorama: H2 2026
MM120Major depressive disorder (MDD)Phase 22027+

Investment thesis

Bull case

MindMed has FDA Breakthrough Therapy designation for the first-ever psychedelic-derived anxiety treatment. Phase 2b data was remarkable: a SINGLE dose of MM120 produced anxiety relief lasting months — something no existing treatment can do. Two Phase 3 trials reading out in 2026 create a clear catalyst path. The GAD market is enormous ($4B+) with terrible current options — SSRIs take weeks to work, cause sexual dysfunction, and require daily dosing forever. MM120 offers a genuine paradigm shift: one supervised session, lasting relief. If Voyage succeeds, MNMD re-rates from speculative micro-cap to legitimate pharmaceutical company. The stock has been beaten down so expectations are low, creating asymmetric upside.

Bear case

Psychedelic medicine has failed to live up to hype repeatedly — MDMA therapy failed its FDA review, Compass Pathways has struggled, and the regulatory path for supervised single-dose treatments is uncharted. Phase 3 trials are much harder to execute than Phase 2 because you need rigorous placebo controls in psychiatry trials where placebo response rates are notoriously high (30-40%). The 12-week efficacy signal from Phase 2 might not hold over the longer Phase 3 duration. MindMed needs BOTH Voyage and Panorama to succeed for a strong NDA — if one fails, the whole thesis collapses. $260M cash with a $35M quarterly burn gives only 2 years of runway. And there's significant stigma risk: regulatory agencies may impose such restrictive REMS requirements that commercial adoption is impractical.

Key upcoming catalysts

No upcoming catalyst for MindMed has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Risk factors

High placebo response rate in psychiatry trials (30-40%) could mask MM120 efficacy in Phase 3

Single-dose treatment model is unprecedented — FDA may require additional long-term safety data

REMS requirements could make commercial distribution impractical for a supervised psychedelic

Societal and political backlash against psychedelic medicine could affect regulatory decisions

Only 24 months of cash runway — Phase 3 failure would require immediate capital raise at distressed levels

Chart MNMD on TradingView — used by 30M+ tradersvia TradingView · Affiliate

Comparable companies

CMPSATAIBXRXLNTHPRAX

Financial snapshot

These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.

Cash

$260M as of Q4 2025

Q4 2025 — 3 quarters ago

Quarterly burn

$35M

Cash runway

~22 months

$260M ÷ $35M per quarter

Revenue

pre revenue

Institutional ownership

42%

Source: company profile text. These figures come from the company profile text, not from a filing we have parsed. Check them against the latest 10-Q before relying on them.

These figures are out of date

The cash position cited here is from Q4 2025, roughly 3 quarters ago. The company has almost certainly reported since. Check its latest filing before using any of this.

Sponsored

Get premium MNMD analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Cash against the next catalyst

Funded through this catalyst

Cash reaches roughly Q3 2027 on the disclosed figures, about 6 quarters past this Q1 2026 catalyst — the readout is funded without a raise.

  • Derived from $260M ÷ $35M per quarter, both self-reported.
  • Burn usually rises as a programme moves through late-stage trials, so this is an upper bound.
  • The cash figure is from Q4 2025, about 3 quarters ago. The company has almost certainly reported since.

This is the arithmetic between two dates, not a forecast. Companies raise early from strength, delay programmes, partner, or borrow.